Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8( ) TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas

Grants

Funding Acknowledgements

[ "We thank all the study participants who contributed to this study and all the researchers, clinicians, and technical and administrative staff who have made this work possible. This research was funded in part by the Janet D. Cottrelle Foundation and the Canadian Institutes of Health Research (Early Career Investigator Grant to MS Anglesio). K Heinze is funded through a research scholarship by the Deutsche Forschungsgesellschaft (HE 8699/1-1). A Talhouk is funded through a Michael Smith Foundation for Health Research Scholar Award. M Kobel received support through the Calgary Laboratory Services research support fund (RS19-612). We thank Shuhong Liu and Young Ou (Anatomical Pathology Research Laboratory) for performing immunohistochemistry. MS Anglesio is funded through a Michael Smith Foundation for Health Research Scholar Award and the Janet D. Cottrelle Foundation Scholars program managed by the BC Cancer Foundation. BC's Gynecological Cancer Research team (OVCARE) receives support through the BC Cancer Foundation and the VGH & UBC Hospital Foundation. This study uses resources provided by the Canadian Ovarian Cancer Research Consortium's COEUR biobank funded by the Terry Fox Research Institute and managed and supervised by the Centre hospitalier de l'Universite de Montreal (CRCHUM). The Consortium acknowledges contributions to its COEUR biobank from Institutions across Canada (for a full list see https://www.tfri.ca/coeur).", "Ovarian tumour tissue analysis consortium studies were supported through independent mechanisms. The WMH study was supported by the Westmead Hospital Department of Gynaecological Oncology. The Gynaecological Oncology Biobank at Westmead, a member of the Australasian Biospecimen Network Oncology group, was funded by the National Health and Medical Research Council Enabling Grants ID 310670 & ID 628903 and the Cancer Institute NSW Grants ID 12/RIG/1-17 & 15/RIG/1-16. The Westmead GynBiobank acknowledges financial support from the Sydney West Translational Cancer Research Centre. The Sydney West Translational Cancer Research Centre is funded by the Cancer Institute NSW. The BGS is funded by Breast Cancer Now and the Institute of Cancer Research (ICR). ICR acknowledges NHS funding to the NIHR Biomedical Research Centre. We thank the study staff, study participants, doctors, nurses, health care providers, and health information sources who have contributed to the study. The SWE study, KS, CM, AL, and the GynCancer Biobank in Western Sweden is financed by Swedish Cancer Foundation (KS), Swedish state under the agreement between the Swedish government and the county council, the ALF-agreement (KS), and Assar Gabrielsson Foundation (CM, AL). The DOV study is funded by National Health Institute grants ID R01-CA168758, R01-CA112523, and R01-CA087538. The GER study was supported by the German Federal Ministry of Education and Research, Programme of Clinical Biomedical Research (01 GB 9401) and the German Cancer Research Center (DKFZ), and thanks Sabine Behrens for competent technical assistance. The HAW study was funded by National Institutes of Health and National Cancer Institute Grants ID N01-CN-25403/CN, N01-CN-67001/CN, P30-CA-71789/CA, and R01-CA-58598/CA. The HOP study was supported by National Institutes of Health and National Cancer Institute Grants ID K07-CA80668, R01CA095023, and R01 CA126841, as well as by US Army Medical Research and Materiel Command DAMD17-02-1-0669 and NIH/National Center for Research Resources/General Clinical Research Center grant MO1RR000056. MW is funded by the European Research Council Advanced Grant (H2020 BRCA-ERC under Grant Agreement No. 742432). The University of Cambridge has received salary support for author PDPP from the NHS in the East of England through the Clinical Academic Reserve. The SEA study (SEARCH) was supported through grants from Cancer Research UK (C490/A10119 C490/A10124 C490/A16561) and the UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge." ]